Development and validation of a risk score to prioritize patients for evaluation of access stenosis
Abstract
Background: Access flow dysfunction, often associated with stenosis, is a common problem in hemodialysis access and may result in progression to thrombosis. Timely identification of accesses in need of evaluation is critical to preserving a functioning access. We hypothesized that a risk score using measurements obtained from the Vasc-Alert surveillance device could be used to predict subsequent interventions.
Methods: Measurement of five factors over the preceding 28 days from 1.46 million hemodialysis treatments (6163 patients) were used to develop a score associated with interventions over the subsequent 60 days. The score was validated in a separate dataset of 298,620 treatments (2641 patients). Results: Interventions in arteriovenous fistulae (AVF; n = 4125) were much more common in those with the highest score (36.2%) than in those with the lowest score (11.0). The score also was strongly associated with interventions in patients with an arteriovenous graft (AVG; n = 2,038; 43.2% vs. 21.1%). There was excellent agreement in the Validation datasets for AVF (OR = 2.67 comparing the highest to lowest score) and good agreement for AVG (OR = 1.92).
Conclusions
This simple risk score based on surveillance data may be useful for prioritizing patients for physical examination and potentially early referral for intervention.
Astor BC, Hirschman K, Kennedy J, Frinak S, Besarab A.
—Semin Dial., October 12, 2021
Sentinel Vascular Access Monitoring after Endovascular Intervention Predicts Access Outcome
Results
Analysis of 138 subjects (females 51%; Black 87%) included 64 arteriovenous fistulas with 104 angioplasties and 74 arteriovenous grafts with 134 angioplasties. The area under the receiver operating characteristic curve for fistula failure at 3 months was 0.59, with optimal screening characteristics of 33.3%, sensitivity of 56.1%, and specificity of 63.2%. Arteriovenous fistula with <33.3% decline compared to >33.3% required earlier subsequent procedure (136 vs 231 days), lower survival on Kaplan–Meier analysis (P = 0.01), and twofold greater risk of failure (P = .006). Area under the receiver operating characteristic for arteriovenous graft failure at 3 months had a sensitivity of 52.3% and specificity of 67.4%. Arteriovenous graft with a post-intervention vascular access pressure ratio decline of <28.8% also required earlier subsequent procedure (144 vs 189 days), lower survival on Kaplan–Meier (P = 0.04), and a 59% higher risk for failure. The area under the receiver operating characteristic curve for combined access failure (arteriovenous fistula + arteriovenous graft) at 3 months had an optimal cut-point value of 31.2%, a sensitivity of 54.6%, and a specificity of 63.1%. Access with a <31.2% drop had a 62% increase in the risk of failure (hazard ratio 1.62; confidence interval 1.16, 2.27; P = 0.005).
Conclusion
The magnitude of post-intervention reduction in vascular access pressure ratio provides a novel predictive measure of access outcomes.
Lalathaksha Kumbar, Ed Peterson, Matthew Zaborowicz, Anatole Besarab, Jerry Yee, Gerard Zasuwa
—The Journal of Vascular Access, 2018
The “Unappreciated” Other Half of Vascular Access Success
Abstract
Extending the life of an AV access (survival) is the goal of an access maintenance program. To determine if the use of Vasc-Alert extended the life of accesses, treatment data was examined at 15 facilities that were considered to have good vascular access maintenance programs. 494 Pts were identified to have started on a new access (389 AVF, 105 AVG). These accesses were then followed forward in time for 4-years until they either transitioned to a new access or the end of the 4-year period, with the results being entered into a Kaplan-Meier survival curve. For comparison, 13 published studies (2,508 Pts) using Kaplan-Meier analysis for AV access patients were examined and combined into a median result. The Kaplan-Meier survival rate for 389 AVF accesses at facilities using Vasc-Alert was 79% at 48 months compared to an expected benchmark survival of 44%. The survival of 105 AVG was 67% at 36 months compared to the benchmark of 35%.
Conclusion
The results of the survival analysis indicate that Vasc-Alert, in concert with a vascular access management program, extending the patency of both AVF and AVG.
Anatole Besarab, John Kennedy, Chaim Charytan, Kim Hirschman, Farhanah Yousaf
—Poster presented at NIH meeting on vascular access, 2015
The Usefulness of Vasc-Alert to Identify Significant Dialysis Access Stenosis
Abstract
One hundred twenty-nine (129) patients were sent for diagnostic angiography. All but five (5) patients (3.8%) had a significant stenosis and were successfully treated with angioplasty. No patients had a thrombosis episode in the study period. None missed any dialysis treatments and the stenosis pre-procedure was significantly less than those sent from other methods of surveillance (71% stenosis for study patients vs. 89% for patients referred from other surveillance methods).
Conclusion
Vasc-Alert is an effective tool to detect VA stenosis.
Gerald A. Beathard, MD, PhD, FASN, Aris Q. Urbanes, MD, Terry Litchfield
—ASN Conference poster, 2012
Automated Intravascular Access Pressure Surveillance Reduces Thrombosis Rates
Abstract
Thrombosis rates declined progressively for arteriovenous grafts (AVG) during the 18-month intervention period compared with the 6-month baseline period. Arteriovenous fistula (AVF) thrombosis rates decreased during post-intervention months 13-18 during employment of the Vasc-Alert. Combined AVG and AVF thrombosis rates declined from 0.297 events per person-yr to 0.133 at the completion of the 18 intervention period, a decline of 55%.
Conclusion
The use of Vasc-Alert can reduce thrombosis rates in vascular accesses, and the magnitude of the effect is larger and more consistent in arteriovenous grafts (AVGs) than autologous AVFs.
Gerard Zasuwa, Stanley Frinak, Anatole Besarab, Edward Peterson, Jerry Yee
—Semin Dial., Sep-Oct 2010
Mathematical Model Demonstrates Influence of Luminal Diameters on Venous Pressure Surveillance
Abstract
It was found that there is an approximate one-to-one relation between MAP and VP, so VP/MAP is a valid adjustment. Also, the 0.50 threshold successfully identifies most grafts with stenosis of 65% or more. However, the ratio of artery/vein diameters varied widely between patients, and the ratio independently influences VP/MAP. When the inflow artery is relatively narrow, the VP/MAP increase is delayed followed by a more rapid increase as critical stenosis is reached.
Conclusions
VP/MAP is a valid adjustment for the influence of MAP on VP, and the standard VP/MAP threshold of 0.50 warns of the transition to critical stenosis. However, relatively narrow arteries cause a delay followed by a rapid increase in VP/MAP that may not be detected before thrombosis unless measurements are very frequent.
John J. White, Steven A. Jones, Sunanda J. Ram, Steve J. Schwab, and William D. Paulson
—Clin J Am Soc Nephrol 2: 681-687, 2007
Vasc-Alert is an Effective Tool to Predict Venous Stenosis
Abstract
110 subjects were sent for 133 venograms. 20 patients had a thrombotic event. The events were analyzed and sensitivity and specificity were found to be 90%. The positive predictive value was 93%, with a negative predictive value of 88%. The false-positive rate was 10%. Fistulas showed more central lesions than grafts.
Conclusion
Vasc-Alert is a clinically useful tool to predict venous stenosis.
Mary Hammes, D.O., Brian Funaki, MD, Kim Hirschman, M.A., John Kennedy, MBA, Ogbannaya Aneziokoro, MD
—ASN Conference poster, 2005
Dynamic venous access pressure ratio test for hemodialysis access monitoring.
Abstract
During a 3-month interval, 120 HD patients with AVGs were assessed by Vasc-Alert while access outcomes were monitored for another 3 months. Sensitivity and specificity for detection of a graft event were 70% +/- 8% and 88% +/- 2% and increased to 74% +/- 5% and 92% +/- 3% at 6 months, respectively.
Conclusion
The Vasc-Alert test is a valuable tool to prospectively monitor for adverse AVG events.
Stanley Frinak,, Gerard Zasuwa, Thomas Dunfee, Anatole Besarab, Jerry Yee
—Am J Kidney Dis., Oct 2002